Alert icon

To align with industry best practices for security and data integrity, Project Data Sphere is requiring users to upgrade their browsers to one that supports encryption protocol TLS 1.2 by December 15, 2017. On that date, Project Data Sphere will disable support of browsers that permit SSL 3.0/TLS 1.0. To prevent any disruption to your access to Project Data Sphere, you must take action.
This browser was not recognized and may not be compatible with TLS 1.2 or higher. Please check with the browser's developer to confirm.
To view information about this, please visit the FAQ. If you have any further questions, please contact us.

Back to the List
Type(s) of Cancer
Study Phase
Phase 2
Study Completion Date
August 2014
NCT00861705Uploaded 01-07-2023
Access via NCI by Request
PDS UID: nci-data-505
Randomized Phase II 2 x 2 Factorial Trial of the Addition of Carboplatin +/- Bevacizumab to Neoadjuvant Weekly Paclitaxel Followed by Dose-Dense AC in Hormone Receptor-Poor/HER2-Negative Resectable Breast Cancer
Files: NCT00861705-D1
Data DictionaryNCT00861705-D1-Data-Dictionary_1.pdf
Files: NCT00861705-D2
Data DictionaryNCT00861705-D2-Data-Dictionary_1.pdf